Eye on Ocular Health

This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.

What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.

What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.

The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.

The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.

John Hovanesian, MD, joins Neda Shamie, MD, to discuss a study that compared two approaches to IOL planning—a traditional manual method versus novel online software. Find out how they stacked up against each other.

To access the full review, please visit the link here.

Inder Paul Singh, MD, sits down with Neda Shamie, MD, to discuss a retrospective analysis that evaluated the Medicare claims–based 5-year economic and reintervention burden for patients with primary open-angle glaucoma after incisional glaucoma surgery in the United States. What do the findings suggest for clinical and surgical practice?

To access the full review, please visit the link here.

Julie Schallhorn, MD, joins Neda Shamie, MD, to discuss a review conducted by the AAO of the published literature on the safety and efficacy of presbyopia-correcting IOLs available in the United States. Learn more about the findings.

To access the full review, please visit the link here.

Marguerite McDonald, MD, FACS, and Neda Shamie, MD, discuss a literature review and panel discussion that sought to develop a consensus statement on the classification of presbyopia by severity. What were the results?

To access the full review, please visit the link here.

Jason Bacharach, MD, sits down with Neda Shamie, MD, to discuss a randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial that evaluated the IOP-lowering efficacy and safety of the bimatoprost implant (Durysta, Allergan) in patients with open-angle glaucoma or ocular hypertension. What were the results?

To access the full review, please visit the link here.